Winst gevend schreef op 4 november 2025 10:07:
.
.
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX)
reported strong revenue growth for Orladeo,
with a 37% year-over-year increase,
indicating robust demand and market acceptance.
The company raised its Orladeo revenue guidance
to between $590 and $600 million for the year, reflecting confidence
in continued growth despite new competition.
De een zijn brood....................